Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy

Shabalin, I.G.; Czub, M.P.; Majorek, K.A.; Brzeziński, Dariusz; Grabowski, M.; Cooper, David R.; Panasiuk, Mateusz; Chruszcz, M.; Minor, Władek

doi:10.1107/s2052252520012944

Cited by 13 publications

(14 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Life-threatening lung-damage and inflammation have been reported in critically and severely ill Covid patients. Dexamethasone and Prednisolone, two well-known exogenous glucocorticoids with their anti-inflammatory and immunomodulating properties may thus be able to ramp down the excessive COVID-19 symptoms (Favalli et al, 2020 ; Shabalin et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19)

Sarkar

Sen

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

The ongoing outbreak of Coronavirus disease 2019 (COVID-19) is a matter of great concern. Although the mortality rate caused by this virus is less than that of SARS and MERS, it is showing higher efficacy in terms of human-to-human transmission. Several strategies have been taken by scientists and researchers worldwide to combat this virus. Numerous phytochemicals and synthesized chemicals are under incessant inspection to obtain a potent anti-covid drug. Since, till now no precise therapy is available for covid patients, researchers are trying to categorize all possible anti-covid substances. Repurposing of drugs and combined drug therapy are becoming popular in treating such viral diseases. In this study, we are proposing the repurposing of three chemicals-Dextromethorphan, Prednisolone and Dexamethasone as anti-covid agents. We have used the tertiary structure of Coronavirus main protease (M pro) with PDB ID 6LU7 as the target protein in this analysis. Molecular docking and dynamics study further revealed their synergistic effect against the COVID-19 protease protein.

show abstract

Section: Resultsmentioning

confidence: 99%

In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19)

Sarkar

Sen

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

show abstract

“…Furthermore, hyperthyroidism fosters albumin synthesis and secretion, and the contrary is observed in hypothyroidism [138]. Considering that albumin regulates dexamethasone distribution and bioavailability, thyroid dysfunction may affect dexamethasone pharmacokinetic influencing this variable [139].…”

Section: Does Medical Management Of Covid-19 Interfere With Thyroid Function?mentioning

confidence: 99%

Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects

Lisco

Tullio

Jirillo

et al. 2021

J Endocrinol Invest

View full text Add to dashboard Cite

Background Thyroid dysfunction has been observed in patients with COVID-19, and endocrinologists are requested to understand this clinical issue. Pandemic-related restrictions and reorganization of healthcare services may affect thyroid disease management. Objective and methods To analyze and discuss the relationship between COVID-19 and thyroid diseases from several perspectives. PubMed/MEDLINE, Google Scholar, Scopus, ClinicalTrial.gov were searched for this purpose by using free text words and medical subject headings as follows: “sars cov 2”, “covid 19”, “subacute thyroiditis”, “atypical thyroiditis”, “chronic thyroiditis”, “hashimoto’s thyroiditis”, “graves’ disease”, “thyroid nodule”, “differentiated thyroid cancer”, “medullary thyroid cancer”, “methimazole”, “levothyroxine”, “multikinase inhibitor”, “remdesivir”, “tocilizumab”. Data were collected, analyzed, and discussed to answer the following clinical questions: “What evidence suggests that COVID-19 may induce detrimental consequences on thyroid function?"; "Could previous or concomitant thyroid diseases deteriorate the prognosis of COVID-19 once the infection has occurred?”; “Could medical management of thyroid diseases influence the clinical course of COVID-19?”; “Does medical management of COVID-19 interfere with thyroid function?”; “Are there defined strategies to better manage endocrine diseases despite restrictive measures and in-hospital and ambulatory activities reorganizations?”. Results SARS-CoV-2 may induce thyroid dysfunction that is usually reversible, including subclinical and atypical thyroiditis. Patients with baseline thyroid diseases are not at higher risk of contracting or transmitting SARS-CoV-2, and baseline thyroid dysfunction does not foster a worse progression of COVID-19. However, it is unclear whether low levels of free triiodothyronine, observed in seriously ill patients with COVID-19, may worsen the disease's clinical progression and, consequently, if triiodothyronine supplementation could be a tool for reducing this burden. Glucocorticoids and heparin may affect thyroid hormone secretion and measurement, respectively, leading to possible misdiagnosis of thyroid dysfunction in severe cases of COVID-19. High-risk thyroid nodules require a fine-needle aspiration without relevant delay, whereas other non-urgent diagnostic procedures and therapeutic interventions should be postponed. Discussion Currently, we know that SARS-CoV-2 could lead to short-term and reversible thyroid dysfunction, but thyroid diseases seem not to affect the progression of COVID-19. Adequate management of patients with thyroid diseases remains essential during the pandemic, but it could be compromised because of healthcare service restrictions. Endocrine care centers should continuously recognize and classify priority cases for in-person visits and therapeutic procedures. Telemedicine may be a useful tool for managing patients not requiring in-person visits.

show abstract

“…Dexamethasone is transported in the body through binding to serum albumin. The binding site for dexamethasone in albumin is the same with testosterone and NSAIDs, and therefore this competition should be considered (Shabalin et al, 2020[ 116 ]). Dexamethasone is well tolerated as a widely used corticosteroid in short-term or single-dose use, but with increasing the dose or duration of therapy, a number of side effects appear.…”

Section: Specific Side Effects Of Corticosteroidsmentioning

confidence: 99%

A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms

Langarizadeh

Tavakoli

Abiri

et al. 2021

EXCLI Journal; 20:Doc339; ISSN 1611-2156

View full text Add to dashboard Cite

Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy

Cited by 13 publications

References 80 publications

In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19)

In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19)

Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects

A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms

Contact Info

Product

Resources

About